McGehee C, Mori Y
NPJ Syst Biol Appl. 2024; 10(1):140.
PMID: 39614108
PMC: 11607384.
DOI: 10.1038/s41540-024-00461-2.
Kunachowicz D, Klosowska K, Sobczak N, Kepinska M
Nanomaterials (Basel). 2024; 14(17).
PMID: 39269086
PMC: 11396817.
DOI: 10.3390/nano14171424.
Al-Ziftawi N, Elazzazy S, Alam M, Shafie A, Hamad A, Bbujassoum S
Front Oncol. 2024; 13:1203684.
PMID: 38162489
PMC: 10757634.
DOI: 10.3389/fonc.2023.1203684.
Schlefman J, Brenin C, Millard T, Dillon P
Med Oncol. 2023; 41(1):19.
PMID: 38103078
DOI: 10.1007/s12032-023-02255-8.
Engel-Nitz N, Johnson M, Johnson M, Cha-Silva A, Kurosky S, Liu X
Patient Prefer Adherence. 2023; 17:1049-1062.
PMID: 37096162
PMC: 10122484.
DOI: 10.2147/PPA.S401480.
Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.
Sheean P, Gomez-Perez S, Joyce C, OConnor P, Bojko M, Smith A
Breast Cancer Res Treat. 2021; 190(1):121-132.
PMID: 34389926
DOI: 10.1007/s10549-021-06358-6.
Defining health-related quality of life in localized and advanced stages of breast cancer - the first step towards hereditary cancer genetic counseling.
Zigman T, Luksa I, Mihaljevic G, Zarkovic M, Kirac I, Vrdoljak D
Acta Clin Croat. 2021; 59(2):209-215.
PMID: 33456106
PMC: 7808234.
DOI: 10.20471/acc.2020.59.02.02.
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
Bjelic-Radisic V, Fitzal F, Knauer M, Steger G, Egle D, Greil R
BMC Cancer. 2020; 20(1):392.
PMID: 32375735
PMC: 7204290.
DOI: 10.1186/s12885-020-06894-2.
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).
Lopez-Tarruella S, Escudero M, Pollan M, Martin M, Jara C, Bermejo B
Sci Rep. 2019; 9(1):20081.
PMID: 31882586
PMC: 6934456.
DOI: 10.1038/s41598-019-55765-9.
Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
Lux M, Bohme S, Hucherig S, Jeratsch U, Kurschner N, Luftner D
Breast Cancer Res Treat. 2019; 176(3):495-506.
PMID: 31065873
PMC: 6586722.
DOI: 10.1007/s10549-019-05262-4.
Cancer symptom response as an oncology clinical trial end point.
Bouchard L, Aaronson N, Gondek K, Cella D
Expert Rev Qual Life Cancer Care. 2019; 3(2-3):35-46.
PMID: 31020045
PMC: 6476191.
DOI: 10.1080/23809000.2018.1483193.
Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.
Galipeau N, Klooster B, Krohe M, Tang D, Revicki D, Cella D
J Patient Rep Outcomes. 2019; 3(1):10.
PMID: 30734110
PMC: 6367496.
DOI: 10.1186/s41687-019-0098-1.
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Breast Cancer (Dove Med Press). 2018; 10:69-78.
PMID: 29765247
PMC: 5942170.
DOI: 10.2147/BCTT.S162841.
Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
Echavarria I, Jerez Y, Martin M, Lopez-Tarruella S
Breast Care (Basel). 2017; 12(5):296-302.
PMID: 29234248
PMC: 5704690.
DOI: 10.1159/000481656.
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?.
Palumbo R, Sottotetti F, Bernardo A
Ther Adv Med Oncol. 2016; 8(3):209-29.
PMID: 27239239
PMC: 4872255.
DOI: 10.1177/1758834016639873.
Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills.
Graf J, Simoes E, Wisslicen K, Rava L, Walter C, Hartkopf A
Geburtshilfe Frauenheilkd. 2016; 76(5):535-541.
PMID: 27239062
PMC: 4873300.
DOI: 10.1055/s-0042-105872.
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R, Sottotetti F, Trifiro G, Piazza E, Ferzi A, Gambaro A
Drug Des Devel Ther. 2015; 9:2189-99.
PMID: 25931813
PMC: 4404936.
DOI: 10.2147/DDDT.S79563.
Treatment priorities in oncology: do we want to live longer or better?.
Marta G, Del Nero L, Marta G, Mangabeira A, Critchi G, Kovacs M
Clinics (Sao Paulo). 2014; 69(8):509-14.
PMID: 25141108
PMC: 4129550.
DOI: 10.6061/clinics/2014(08)02.
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
Lum D, Perel P, Hingorani A, Holmes M
PLoS One. 2013; 8(10):e76648.
PMID: 24098545
PMC: 3788742.
DOI: 10.1371/journal.pone.0076648.
Psychological interventions for women with metastatic breast cancer.
Mustafa M, Carson-Stevens A, Gillespie D, Edwards A
Cochrane Database Syst Rev. 2013; (6):CD004253.
PMID: 23737397
PMC: 11032751.
DOI: 10.1002/14651858.CD004253.pub4.